Calypso Biotech – auto-immune diseases

Calypso Biotech is a biotech company developing antibody therapies up to clinical proof-of-concept by leveraging its expertise in immunology and drug development. Calypso Biotech’s portfolio consists of two therapeutic antibody programs planned to reach the clinic by 2016-2017 against gastro-intestinal auto-immune syndromes such as Crohn’s and Refractory Celiac diseases.

Calypso Biotech – auto-immune diseases

calypso biotech Continue reading

Apexigen – rabbit-derived humanized monoclonal antibodies

Apexigen is a pioneer biotech company for antibody therapeutics based on rabbit-derived humanized monoclonal antibodies, allowing therapeutic benefits that have not been achieved through the use of other technologies. Thanks to its proprietary platform technology, Apexigen has built a strong pipeline of humanized monoclonal antibody programs spanning from oncology, inflammatory disease and ophthalmology.

Apexigen – rabbit-derived humanized monoclonal antibodies

Apexigen

Continue reading